Open AccessDiffering Effects of Aliskiren/Amlodipine Combination and High‐Dose Amlodipine Monotherapy on Ambulatory Blood Pressure and Target Organ Protection
Author(s) -
Mizuno Hiroyuki,
Hoshide Satoshi,
Fukutomi Motoki,
Kario Kazuomi
Publication year - 2016
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12618
Subject(s) - medicine , amlodipine , aliskiren , ambulatory , blood pressure , ambulatory blood pressure , pharmacology , cardiology , renin–angiotensin system
The aim of this study was to compare an aliskiren/amlodipine combination with high‐dose amlodipine monotherapy on ambulatory blood pressure monitoring ( ABPM ) and organ protection. The study was a prospective, randomized, multicenter, open‐label trial in elderly essential hypertensive patients. A total of 105 patients with clinic BP ( CBP ) ≥140/90 mm Hg with amlodipine 5 mg were randomly allocated to aliskiren (150–300 mg)/amlodipine (5 mg) ( ALI / AML group, n=53) or high‐dose amlodipine (10 mg) (h‐ dAML group, n=52) and treated for 16 weeks. Each patient's CBP , ABPM , urine albumin‐to‐creatinine ratio ( UACR ), and brachial‐ankle pulse wave velocity (ba PWV ) were measured at baseline and at the end of the study. The ALI / AML and h‐ dAML groups showed similarly reduced mean 24‐hour SBP , daytime SBP , nighttime SBP , and ba PWV . However, UACR reduction was significantly greater in the ALI / AML group ( P =.02). ALI / AML was significantly less effective in reducing early‐morning BP ( P =.002) and morning BP surge ( P =.001) compared with h‐ dAML .